ADCT
ADC Therapeutics SA
NYSE: ADCT · HEALTHCARE · BIOTECHNOLOGY
$3.78
+0.27% today
Updated 2026-04-29
Market cap
$480.78M
P/E ratio
—
P/S ratio
5.91x
EPS (TTM)
$-1.12
Dividend yield
—
52W range
$1 – $5
Volume
0.9M
ADC Therapeutics SA (ADCT) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-175.30%
Operating margin
-69.30%
ROE
-706.00%
ROA
-20.60%
Debt/equity
-0.49x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | $1.80M | $-89.86M | -4,643.76% | -5,084.30% | -4,984.03% |
| 2018 | $1.14M | $-123.10M | -10,258.42% | -11,047.46% | -10,797.89% |
| 2019 | $2.34M | $-116.48M | 100.00% | -5,102.52% | -4,977.95% |
| 2020 | $0.00 | $-246.29M | — | — | — |
| 2021 | $33.92M | $-230.03M | 95.89% | -771.65% | -678.20% |
| 2022 | $209.91M | $-157.13M | 98.43% | -58.76% | -74.86% |
| 2023 | $69.56M | $-240.05M | 96.36% | -238.63% | -345.11% |
| 2024 | $70.84M | $-157.85M | 91.60% | -184.44% | -222.83% |
| 2025 | $81.36M | $-142.62M | 90.57% | -133.21% | -175.31% |